Sponsors (3)
The bill strengthens patient safety and regulatory oversight for medical devices (including cross-border reporting and validated reprocessing tests) but does so by imposing meaningful compliance, timing, and confidentiality costs on manufacturers that could raise prices, slow innovation, and increase regulatory workload.
Patients, hospitals, and clinicians will be safer because mandatory pre-change notifications and required reporting of foreign safety/design communications let FDA/HHS detect, act on, and remove unsafe device modifications or risks sooner.
Hospitals, clinicians, and patients benefit from required validated reprocessing instructions and rapid assessment tests for reusable devices, which should reduce device-related infections and increase clinician confidence in reprocessing.
Government agencies and the public gain stronger regulatory tools and better situational awareness — treating failures to report as adulteration and receiving foreign-safety notices improves the ability to issue guidance, recalls, and prepare for cross-border device issues.
Device manufacturers — especially small businesses — will face higher compliance, administrative, and development costs (including for validated tests), plus increased legal exposure, which could raise device prices, reduce competition, and slow innovation.
Patients and hospitals could see delays in receiving safety or efficiency improvements because manufacturers may postpone changes or market entry while navigating reviews or avoiding enforcement risk.
HHS/FDA may face increased regulatory workload and possible delays in responses or other device reviews due to potential over-reporting of foreign communications and tighter documentation requirements.
Based on analysis of 4 sections of legislative text.
Introduced March 26, 2025 by Ted Lieu · Last progress March 26, 2025
Requires medical device manufacturers to notify the Secretary of Health and Human Services before making device design changes or changes to reprocessing instructions for devices sold in interstate commerce, and to notify within 5 calendar days after certain communications to foreign health care providers about design, reprocessing, or safety issues. Failure to meet the new notification duties is treated as adulteration. The bill also expands the legal definition of device to expressly cover rapid assessment tests used to confirm proper reprocessing of reusable devices and directs the Secretary to publish, within one year, an initial list of such tests that must include validated instructions and validation data in 510(k) submissions; FDA may not accept 510(k)s for listed test types unless those materials are provided. These changes create new pre-change notice and short-timeline foreign-notification duties for manufacturers, add an enforcement consequence (adulteration) for noncompliance, clarify what counts as a reusable device and related rapid tests, and impose a one-year regulatory deadline for the agency to require specified validation documentation as a condition of 510(k) acceptance for listed rapid assessment tests.